newsfilter
← Latest News
Business Wire·

Elan Announces Closing of TYSABRI® Collaboration Transaction with Biogen Idec

DUBLIN--(BUSINESS WIRE)--Elan Corporation, plc (NYSE:ELN) is pleased to announce the closing today of the TYSABRI® (natalizumab) Collaboration Transaction with Biogen Idec. The agreement was announced on February 6, 2013.